載入中
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
前收盤價
US$3.29
−US$0.13 · -3.80%
盤中時間採用ET。市場資料可能有所延遲。
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
日內區間
目前US$3.29
52週區間
目前US$3.29
盤中時間採用ET。市場資料可能有所延遲。
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
日內區間
目前US$3.29
52週區間
目前US$3.29
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3.49億 USD | 2.86億 USD | 1.99億 USD | 9977萬 USD | 7544.2萬 USD |
| 銷貨成本 | 6116萬 USD | 7660.2萬 USD | 6277.1萬 USD | 5749.7萬 USD | 3885.7萬 USD |
| 毛利 | 2.88億 USD | 2.09億 USD | 1.36億 USD | 4227.3萬 USD | 3658.5萬 USD |
| 研究與開發 | 6634.8萬 USD | 4589.3萬 USD | 3128.3萬 USD | 1972.1萬 USD | 1231.2萬 USD |
| 銷售、一般及管理費用 | 1.44億 USD | 9432.9萬 USD | 9431.4萬 USD | 9147.3萬 USD | 7741.7萬 USD |
| 營業費用 | 2.49億 USD | 1.36億 USD | 1.28億 USD | 1.06億 USD | 8360.7萬 USD |
| 利息收入 | — | 1261.5萬 USD | 615.4萬 USD | 251.3萬 USD | 11.2萬 USD |
| 利息支出 | 1383萬 USD | 3798.1萬 USD | 2516.1萬 USD | 2476.9萬 USD | 1657.7萬 USD |
| 折舊和攤銷 | 1228.4萬 USD | 896.8萬 USD | 580.1萬 USD | 631.2萬 USD | 324.4萬 USD |
| 營業利益 | 3880.1萬 USD | 7258.7萬 USD | 867.8萬 USD | −6411萬 USD | −4702.2萬 USD |
| 淨利 | 586.3萬 USD | 2758.8萬 USD | −1193.8萬 USD | −8740萬 USD | −8092.6萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$10.00
上漲空間 203.95%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3740.26萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM2847.26萬0.04%787.4億 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI2483.88萬0.25%98.74億 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF1436.5萬0.01%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO1004.81萬0.07%139.17億 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB813.33萬0.08%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO709.04萬0.04%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA586.88萬0.03%218.24億 USD0.03%US$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
